Pipeline

By leveraging our deep expertise in protein drug discovery, our pipeline of enhanced cytokines have been specifically curated to target clinically validated as well as emerging mechanisms, positioning our portfolio to pursue both best-in-class and first-in-class approaches.

ProgramLead IDLead OPIND Enabling StudiesClinic
BPT-143
IL-2 for Immuno-oncology

 

IL-2 is a powerful immune-stimulating cytokine. Proleukin (aldesleukin) which is a recombinant version of IL-2 was discovered over 30 years ago and has been commercially available since 1992 to treat cancer. Unfortunately, several shortcomings including its modest half-life and high toxicity has limited its clinical utility.

Wild type IL-2’s biological effects are mediated by interactions with multiple receptors known as alpha, beta, and gamma. The known toxicity of IL-2 is primarily potentiated by a preferential binding to the alpha receptor, potentially leading to the occurrence of life-threatening toxicities such as vascular leak syndrome. Meanwhile, interaction with the beta receptor is known to selectively expand tumor killing effector T-cells, a desired effect for the treatment of cancer.

BPT-143 is an enhanced, half-life extended, IL-2 cytokine that uses small modifications to amino acid side chains to block binding to IL-2 receptor alpha, and enhance binding to IL-2 receptor beta, allowing it to selectively expand anti-tumor effector T-cells while minimizing known toxicities. We believe BPT-143 exhibits best-in-class IL-2 properties for cancer immunotherapy.

Bright Peak’s IL-2 construct can also be conjugated as a payload to our Immunocytokine platform.
close x
IL-18
Immuno-oncology

 

IL-18 is a strong stimulator of innate and adaptive immunity which makes it a potent and attractive therapeutic candidate for cancer immunotherapy. Native IL-18 cytokines activate the IL-18 receptor but also bind to an IL-18 Binding Protein (IL-18BP) which are frequently upregulated and abundant in the tumor microenvironment. Binding to the IL-18 BP blocks the cytokine from activating its receptor and reach its true target, leading to a ‘quenching’ effect and ultimately tachyphylaxis.

Using its unique EDC technology platform, Bright Peak’s enhanced IL-18 cytokine is specifically engineered to preferentially activate the IL-18 receptor without binding to IL-18BP – triggering potent pro-inflammatory signaling in antitumor immune cells without being neutralized by IL-18BP. Further, Bright Peak’s IL-18 can be conjugated for half-life extension for optimal tumor exposure, and as a payload to our Immunocytokine platform without impacting the cytokine’s improved biological function.
close x
IL-7
Immuno-oncology

 

IL-7 presents a unique opportunity to enhance cancer immunotherapy via multiple complementary mechanisms. Il-7 is a homeostatic cytokine which increases the proliferation and survival of naïve T-cells. In additional to adding greater T-cell diversity, IL-7 may also provide improved durability of current immunotherapy treatments due to enhanced T-cell memory.

Bright Peak’s enhanced IL-7 cytokine is specifically engineered to become a significantly more potent stimulator of T-effector cells compared to native IL-7.
close x
IL-2 AI
Autoimmune

 

The IL-2 cytokine is a growth factor that is critical for the proliferation all T cells. At low concentrations, it is a known activator and expander of regulatory T cells (Tregs), which in turn can regulate immune responses and attenuate autoimmunity.

Bright Peak has engineered an enhanced IL-2 cytokine harboring specific modifications to amino acid side chains to block binding to IL2Rb, and enhance binding to IL2Ra, creating an IL-2 mutein that preferentially expands and activates Tregs. Tregs have been shown to play a key role in autoimmunity and their expansion and activation is a promising treatment approach for many autoimmune diseases.

Bright Peak’s IL-2 AI molecule can also be conjugated as a payload to antibodies as part of our Immunocytokine platform.
close x
DrugPhase
BPT-143
IL-2 for Immuno-oncology
IND Enabling Studies
IL-18
Immuno-oncology
Lead OP
IL-7
Immuno-oncology
Lead OP
IL-2 AI
Autoimmune
Lead OP

BPT-143

IL-2 is a powerful immune-stimulating cytokine. Proleukin (aldesleukin) which is a recombinant version of IL-2 was discovered over 30 years ago and has been commercially available since 1992 to treat cancer. Unfortunately, several shortcomings including its modest half-life and high toxicity has limited its clinical utility.

Wild type IL-2’s biological effects are mediated by interactions with multiple receptors known as alpha, beta, and gamma. The known toxicity of IL-2 is primarily potentiated by a preferential binding to the alpha receptor, potentially leading to the occurrence of life-threatening toxicities such as vascular leak syndrome. Meanwhile, interaction with the beta receptor is known to selectively expand tumor killing effector T-cells, a desired effect for the treatment of cancer.

BPT-143 is an enhanced, half-life extended, IL-2 cytokine that uses small modifications to amino acid side chains to block binding to IL-2 receptor alpha, and enhance binding to IL-2 receptor beta, allowing it to selectively expand anti-tumor effector T-cells while minimizing known toxicities. We believe BPT-143 exhibits best-in-class IL-2 properties for cancer immunotherapy.

Bright Peak’s IL-2 construct can also be conjugated as a payload to our Immunocytokine platform.

IL-18

IL-18 is a strong stimulator of innate and adaptive immunity which makes it a potent and attractive therapeutic candidate for cancer immunotherapy. Native IL-18 cytokines activate the IL-18 receptor but also bind to an IL-18 Binding Protein (IL-18BP) which are frequently upregulated and abundant in the tumor microenvironment. Binding to the IL-18 BP blocks the cytokine from activating its receptor and reach its true target, leading to a ‘quenching’ effect and ultimately tachyphylaxis.

Using its unique EDC technology platform, Bright Peak’s enhanced IL-18 cytokine is specifically engineered to preferentially activate the IL-18 receptor without binding to IL-18BP – triggering potent pro-inflammatory signaling in antitumor immune cells without being neutralized by IL-18BP. Further, Bright Peak’s IL-18 can be conjugated for half-life extension for optimal tumor exposure, and as a payload to our Immunocytokine platform without impacting the cytokine’s improved biological function.

IL-7

IL-7 presents a unique opportunity to enhance cancer immunotherapy via multiple complementary mechanisms. Il-7 is a homeostatic cytokine which increases the proliferation and survival of naïve T-cells. In additional to adding greater T-cell diversity, IL-7 may also provide improved durability of current immunotherapy treatments due to enhanced T-cell memory.

Bright Peak’s enhanced IL-7 cytokine is specifically engineered to become a significantly more potent stimulator of T-effector cells compared to native IL-7.

IL-2 AI

The IL-2 cytokine is a growth factor that is critical for the proliferation all T cells. At low concentrations, it is a known activator and expander of regulatory T cells (Tregs), which in turn can regulate immune responses and attenuate autoimmunity.

Bright Peak has engineered an enhanced IL-2 cytokine harboring specific modifications to amino acid side chains to block binding to IL2Rb, and enhance binding to IL2Ra, creating an IL-2 mutein that preferentially expands and activates Tregs. Tregs have been shown to play a key role in autoimmunity and their expansion and activation is a promising treatment approach for many autoimmune diseases.

Bright Peak’s IL-2 AI molecule can also be conjugated as a payload to antibodies as part of our Immunocytokine platform.